# A randomized stepped wedge trial of an intensive combination approach to roll back the HIV epidemic in Nigerian Adolescents: iCARE Nigeria treatment support protocol

- 3
- 4 Babafemi O. Taiwo MBBS, FAS,<sup>1</sup> Lisa M. Kuhns, PhD, MPH<sup>2,3</sup>, Olayinka Omigbodun MBBS, MPH, FAS,<sup>4,5</sup>
- 5 Olutosin Awolude MBBS, MSc,<sup>6,7</sup> Kehinde M. Kuti MBBS, MSCI,<sup>7,8</sup> Adedotun Adetunji MBChB, MSCI,<sup>9</sup>
- 6 Baiba Berzins MPH,<sup>1</sup> Patrick Janulis, PhD,<sup>10</sup> Sulaimon Akanmu, MBBS,<sup>11</sup> Oche Agbaji, MBBS, MPH, MD<sup>12</sup>
- 7 Agatha N. David, MBBS, MPH, FMCP<sup>13</sup> Akinsegun Akinbami, MBChB, MPH, MSc, FMCPath<sup>14</sup> Abiodun
- 8 Folashade Adekambi, MBBS, FWACP, MPH<sup>15</sup> Amy K. Johnson, PhD, MSW,<sup>2,3</sup> Ogochukwu Okonkwor,
- 9 MPH,<sup>1</sup> Bibilola D. Oladeji, MBBS, MSc,<sup>9</sup> Marbella Cervantes, MA,<sup>3</sup> Olubusuyi M. Adewumi, PhD,<sup>16</sup> Bill
- 10 Kapogiannis MD, <sup>17</sup> Robert Garofalo MD, MPH<sup>2,3</sup>.
- 11

12	<sup>1</sup> Division of Infectious Diseases and Institute for Global Health, Northwestern University, Chicago, USA
13	<sup>2</sup> Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, USA
14	<sup>3</sup> Division of Adolescent Medicine, Ann and Robert H Lurie Children's Hospital of Chicago, USA
15	<sup>4</sup> Department of Child and Adolescent Psychiatry, and Centre for Child and Adolescent Mental Health, College
16	of Medicine, University of Ibadan, Nigeria
17	<sup>5</sup> Department of Psychiatry, College of Medicine, University of Ibadan, Nigeria
18	<sup>6</sup> Department of Obstetrics and Gynecology, College of Medicine, University of Ibadan, Nigeria
19	<sup>7</sup> Infectious Disease Institute, College of Medicine, University of Ibadan, Nigeria
20	<sup>8</sup> Staff Medical Services Department, University College Hospital, Ibadan, Nigeria

<sup>9</sup>Department of Family Medicine, University College Hospital, Ibadan, Nigeria

- <sup>10</sup>Department of Medical Social Sciences, Northwestern University, Chicago, USA
- <sup>23</sup> <sup>11</sup> Lagos University Teaching Hospital, Lagos, Nigeria
- <sup>12</sup> Department of Medicine, University of Jos and Jos University Teaching Hospital, Jos, Nigeria
- <sup>13</sup> Nigerian Institute of Medical Research, Lagos, Nigeria
- <sup>14</sup> Lagos State University College of Medicine, Ikeja, Nigeria
- <sup>15</sup> Department of Paediatrics, Olabisi Onabanjo University and Olabisi Onabanjo University Teaching Hospital,
- 28 Ogun State, Nigeria
- <sup>16</sup> Department of Virology, College of Medicine, University of Ibadan, Ibadan, Nigeria
- <sup>17</sup> Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland,
- 31 USA
- 32 Corresponding Author:
- 33 Babafemi O. Taiwo, MBBS, FAS
- 34 E-mail address: <u>b-taiwo@northwestern.edu</u>
- 35

36 ABSTRACT (295 words)

Background: Nigeria is one of six countries with half the global burden of youth living with HIV. Interventions to date have been inadequate as AIDS-related deaths in Nigeria's youth have remained unchanged in recent years. The iCARE Nigeria HIV treatment support intervention, a combination of peer navigation and SMS text message medication reminders to promote viral suppression, demonstrated initial efficacy and feasibility in a pilot trial among youth living with HIV in Nigeria. This paper describes the study protocol for the large-scale trial of the intervention.

Methods: The iCARE Nigeria-Treatment study is a randomized stepped wedge trial of a combination (peer 43 navigation and text message reminder) intervention, delivered to youth over a period of 48 weeks to promote 44 viral suppression. Youth receiving HIV treatment at six clinical sites in the North Central and South Western 45 regions of Nigeria were recruited for participation. Eligibility criteria included registration as a patient at 46 participating clinics, aged 15-24 years, on antiretroviral therapy for at least three months, ability to understand 47 and read English, Hausa, Pidgin English, or Yoruba, and intent to remain a patient at the study site during the 48 study period. The six clinic sites were divided into three clusters and randomized to a sequence of control and 49 intervention periods for comparison. The primary outcome is plasma HIV-1 viral load suppression, defined as 50 viral load  $\leq$  200 copies/mL, in the intervention period versus the control period at 48 weeks of intervention. 51 Discussion: Evidence-based interventions to promote viral load suppression among youth in Nigeria are needed. 52 This study will determine efficacy of a combination intervention (peer navigation and text message reminder) 53

- and collect data on potential implementation barriers and facilitators to inform scale-up if efficacy is confirmed.
- 55 Trial registration: ClinicalTrials.gov number, NCT 04950153, retrospectively registered July 6, 2021,

56 <u>https://clinicaltrials.gov/</u>.

57

58 Introduction (3,023 words)

59	Since 2016, guidelines in Nigeria, Africa's most populous country, have recommended antiretroviral therapy
60	(ART) regardless of CD4 cell count for all people with HIV.(1) Effective ART suppresses HIV-1 replication,
61	which curbs AIDS-related morbidity and mortality, limits viral transmission, and is essential to end the
62	epidemic.(2-4) Youth in Nigeria have not benefited from ART as much as adults.(5-8) The United Nations
63	defines youth as individuals aged 15-24, in recognition of the developmental risks to health and well-being of
64	mid-to-late adolescence and young adulthood(9) and has called for their prioritization in national HIV treatment
65	strategies.(10) An estimated 180,000 youth ages 15-24 are living with HIV in the country, with 23,000 new
66	infections in 2020.(11) Viral load suppression is estimated to be approximately 43% across age groups,
67	however, it is significantly lower among youth and younger adults (aged less than 34 years).(12) In 2020, an
68	estimated 3,000 youth died of AIDS-related causes in Nigeria.(11) Effective interventions to promote ART
69	adherence and suppression of HIV-1 viremia are needed to ultimately end the epidemic among vulnerable
70	youth.

71

Peer support, which shifts supportive care to community-based and non-professional providers for efficient use 72 of resources, (13, 14) is recommended by the World Health Organization as a strategy that provides many 73 benefits for youth across the HIV care continuum. (15) Peer support can also motivate and reinforce self-care 74 and help to build self-efficacy for HIV treatment. (15) In addition, mobile technology-based strategies 75 (mHealth) have emerged as a promising approach to deliver HIV-related interventions, particularly among 76 youth, with a growing body of evidence suggesting efficacy. (16-18) Approaches using mHealth have the 77 advantage of simple interfaces for users, accessibility anywhere mobile telephone signals and/or Wi-Fi are 78 available, relative affordability, and have been promoted specifically to reach stigmatized and disenfranchised 79 populations.(19, 20) An SMS text message reminder intervention, the Treatment Text intervention (TXTXT), 80 developed by members of our research team has shown evidence of both feasibility and efficacy to promote 81 ART adherence among youth with HIV in the United States (US) (21). Based on social cognitive theory (22, 82

23), TXTXT is a bi-directional and personalized reminder intervention to promote medication adherence, which
 incorporates environmental cues to action and self-management support and feedback.

85

The iCARE Nigeria initiative includes both an HIV treatment support intervention and an HIV testing 86 promotion intervention (parallel combination interventions). Herein, we describe the treatment support 87 intervention of iCARE Nigeria (iCARE-Treatment), which incorporates locally adapted peer navigation and 88 TXTXT to directly support youth living with HIV and promote viral suppression and is being tested via the 89 UG3/UH3 mechanism, funded by the US National Institutes of Health (NIH). In the UG3 pilot phase of the 90 study, iCARE-Treatment was piloted in a 48-week pre-post trial; participants (N=40) were 50% male, mean age 91 19.9 years (range=15-24), and 55% perinatally infected. Viral suppression (defined as viral load  $\leq 200$ 92 copies/mL) was 35% at baseline and increased to 68% at 24 weeks and 60% at 48 weeks. These increases 93 correspond to an odds ratio (OR) = 14.0 and OR = 6.0, at 24 and 48 weeks, respectively (p values < .05). 94 Participants reported high satisfaction, with 100% indicating that they were satisfied/mostly satisfied with the 95 intervention and 100% would refer a friend to receive it.(24) 96 97

#### 98 Study objectives

<sup>99</sup> The purpose of this study is to assess the efficacy of iCARE-Treatment, a combination peer navigation and text

- message medication reminder intervention, on viral suppression among youth living with HIV, aged 15-24.
- 101 Secondary objectives are to assess intervention effects on ART adherence and retention in HIV care.

102

# 103 Materials and Methods

#### 104 Design

The protocol described herein is presented following the SPIRIT guidelines with related checklist (Figure 1). 105 This study is a randomized stepped wedge trial among six clinical sites in Nigeria. The sites were divided into 106 three clusters consisting of one, three, and two sites respectively. The Cluster 1 sites include the Infectious 107 Disease Institute of the College of Medicine, University of Ibadan (IDI/CoMUI); Cluster 2 sites include Lagos 108 State University Teaching Hospital (LASUTH), Lagos University Teaching Hospital (LUTH), Nigerian 109 Institute of Medical Research (NIMR); and Cluster 3 sites include Jos University Teaching Hospital (JUTH) 110 and Olabisi Onabanio University Teaching Hospital (OOUTH). In addition, IDI/CoMUI and LASUTH have 1 111 and 3 affiliate clinics linked to the sites, respectively, and LUTH, NIMR, JUTH and OOUTH have 2 each. The 112 study duration of 96 weeks consists of four 24-week periods, which include control (pre-intervention), 113 intervention, or follow-up (post-intervention) conditions. Per the stepped wedge design (Figure 2), there are 114 three different sequences: 1) two 24-week intervention periods then two follow-up periods (no control period); 115 2) one 24-week control period followed by two intervention periods then one follow-up period; 3) two 24-week 116 control periods followed by two intervention periods (no follow-up period). Thus, each sequence includes 48 117 continuous weeks of the iCARE-treatment intervention, which consists of peer navigation and support 118 combined with daily text message medication reminders (TXTXT). The control and follow-up periods are 119 observational, with collection of data only, while receiving standard care. 120

# 121 Identification and recruitment of participants

Participants were recruited from youth patients at each clinical site. Individuals were eligible if they were: (a)
living with HIV, (b) a registered patient at a clinical site, (c) aged 15 to 24 years (emancipated or with parental
permission if aged 15), (d) on ART for at least three months and (e) able to understand and read basic English,
Hausa, Pidgin English or Yoruba, (f) willing and able to provide informed assent or consent, and (g) intending
to remain a patient in the study clinic during the study period (up to 96 weeks). Individuals were excluded if

they were: (a) unable to provide informed assent or consent; (b) aged 15 years and are not emancipated or do
not have parental permission for participation.

129

#### 130 Randomization

After the completion of initial enrollment, clusters were randomized to a sequence. Randomized sequences were concealed from participants and study staff until enrollment was completed. The random assignments were generated by a computerized random number generator by the Statistician (PJ). Clusters 2 and 3 were randomized to the sequence with one or two initial control periods (data collection only), respectively, followed by two intervention periods. Given the complexities of analysis, the statistician will not be blinded during statistical analyses.

137 Cluster 1 was not randomized but began the intervention at the point of enrollment, which was purposeful as

this was a test site for the original UG3 pilot trial of the intervention and thus had staff ready and trained to

begin the intervention at the start of the study period. The final sequence of the four 24-week periods in each

cluster is shown in Figure 2. A two-day training was conducted with investigators and staff of clusters 2 and 3

141 after their initial control period (s), immediately prior to intervention deployment (staggered by start date). This

was then followed by intensive step-down trainings at each cluster site with all staff and peer navigators

143 (including alternate/replacement peer navigators), to prepare them to deliver the intervention.

#### 144 Figure 1. SPIRIT Checklist

#### 145 Figure 2. iCARE Study Schema

146

### 147 Description of the intervention period: iCARE-Treatment

148 The iCARE-Treatment intervention includes peer navigation and daily text message medication reminders.

149 After assessment of the participant's needs and development of an action plan, peer navigators make at least one

contact (in-person or phone) every two weeks with participants to support goals of the action plan. Peer support 150 is designed to be dynamic and flexible, with support provided via text message, WhatsApp message, and phone 151 calls and includes accompaniment to the clinic, assistance with medication pick-up, and other health-related 152 appointments, as needed. Peer navigators also work with the study coordinator, project manager and 153 investigators to facilitate referrals to mental health and other services and provide general peer support. Peer 154 navigators are selected based on recommendations from their HIV care providers. Requirements for this role 155 include living with HIV and being virologically suppressed in the prior 12-month period (or the last available 156 viral load measurement), clinically stable according to their physician's subjective assessment, and aged 18-30 157 years. Age range and other targeted attributes of peer navigators are informed by findings from formative 158 research conducted in youth and other stakeholders prior to the UG3 pilot study. Based on findings from the 159 UG3 adaptation and pilot study, (25) we expected to match each peer navigator to 4-5 study participants with 160 salient shared characteristics, such as gender, age group, residential location, education level, religion, and 161 other social characteristics (e.g., marital status, motherhood). Peer navigators receive a monthly stipend to cover 162 cost of transportation and telephone/text messaging plus honorarium for their time. The total amount provided 163 as stipend is based on results of our preparatory stakeholder engagement activities and consistent with local 164 standards. 165

The text message reminder intervention is an mHealth intervention using the TXTXT platform, designed and 166 tested with evidence of efficacy in our prior work in the US.(21, 26) This intervention includes a youth-167 centered, personalized, and bidirectional set of three daily messages to support adherence. The daily text 168 messages include a personalized initial medication reminder that coincides with the participant's chosen time to 169 take their antiretroviral regimen, followed by a second message 15 minutes later, asking whether they took their 170 medication, with a request for reply ("yes" or "no"). An encouraging third automated message, from our text 171 message library, is then triggered by their reply. Both the initial and follow-up messages are chosen by each 172 youth and personalized to reflect content meaningful to them. To protect confidentiality, messages are worded 173 in a way that would not reveal the participant's HIV status if read by a third party. In the UG3 study, youth 174

living with HIV worked with study staff to adapt the text message library to ensure it contained expressions
understood and commonly used by youth locally. The text messages are delivered via the Dimagi Commcare
platform (<u>https://www.dimagi.com/commcare/</u>). Participants use their own phones for text messaging;

- however, a phone is provided to participants who do not have access to a phone, which is anticipated to be less
- than 20% of participants. Participants also receive 100 Nigerian Naira per week during the intervention period
- to cover the (minimal) costs of text messages (i.e., "airtime").

#### 181 Control period:

- 182 During the pre-intervention control periods, study participants receive standard-of-care (SOC) adherence
- counseling only. In Nigeria, per national guidelines,(27) SOC adherence counseling includes a readiness
- assessment at initiation of ART to emphasize both the benefits of medication adherence and also the
- consequences of poor adherence, including virological failure; the development of a patient-centered adherence
- strategy, and on-going monitoring. Two consecutive viral load test results above 1000 copies/mL, at least 3
- 187 months apart, triggers enhanced adherence counseling which includes exploration of specific barriers to
- adherence and development of an adherence intervention plan with follow-up at 3-month intervals.

#### 189 Follow-up period:

This is the post-intervention period when daily text messaging and protocol-specified peer navigation arediscontinued, and participants return to standard care.

192

#### 193 Study Assessments

Participants are consented by study staff at the enrollment visit and complete interviewer-administered computerized study assessments at each visit, at 24-week intervals, captured in REDCap (see Table 1 for full schedule of activities). Study consent includes permission for use of participant data and samples for future studies. The longitudinal module of REDCap with survey queue and scheduling modules is used for both survey data collection and entry of data from case report forms, anchored to the enrollment date. All study data are

- securely stored at Northwestern University in a limited access database by study ID. All hard copy participant
- information (e.g., study checklists, consent forms) are securely stored at each study site in locked file cabinets
- with limited access. Study enrollment and data collection procedures are monitored annually by contractual
- arrangement with a third-party monitor, arranged by the study sponsor.

						Primary outcome: vii
	Pre-intervention (Control Sites)	Baseline (Intervention Phase) Intervention	Week 24- Intervention Phase	Week 48 – Intervention Phase	Post-intervention	load suppression is defined as plasma vir load < 200 copies/mI
Informed consent	Х	X				
Blood draw for viral load	Х	X	Х	Х	Xa	Blood for viral load
Blood draw for CD4 count	Xp	Xp				
Blood draw for future studies (stored; virologic resistance testing and other studies)	x	x	х	х		quantification is colle
Adherence Assessment: Dried Blood Spot (DBS), Pharmacy Pick-up Records Abstraction,(28, 29) Self- Report(30)	x	x	х	х	Xc	via venipuncture at estudy visit. Viral load
Computer Assisted Personal Interviewing Questionnaires <sup>d</sup>	х	x	х	х		quantification is
Implementation Assessment <sup>e</sup>	Х	Х	Х	Х	Х	
Cost Assessment <sup>f</sup>	Х	Х	Х	Х	Х	performed at study
SMS + Peer Navigation		Base	eline through	week 48		1-1
SMS Text Initiation		X				- laboratories using rea
Peer Navigation Enrollment		X				time HIV-1 COBAS
<sup>a</sup> Per medical chart abstraction <sup>b</sup> CD4 quantification will be p in Jos, Lagos, Sagamu), or b <sup>c</sup> Medical records abstraction <sup>d</sup> Computer assisted person treatment knowledge,(31) depressive symptoms,(34) acceptability(36) <sup>e</sup> RE-AIM framework implem Consolidated Framework fo	erformed only at t aseline (in Ibadar only (no self-repo al interviewing (C HIV medicatic alcohol and dru entation strategie	he first study n) ort, no DBS) API): Demog on self-effici g use,(35) in es,(37) conte Research (C	visit (either p graphic Char acy(32), H ntervention extual factors FIR).(38)	ore-interventior acteristics, HI IV stigma,(33 satisfaction ar s from the	V 3)	assay (Roche Molecu Systems, Inc.) with a lower detection limit 20 copies/mL.

Retention in HIV care is defined as at least two medical visits in a 24-week study period (39), with clinic visits

abstracted from the medical record. ART adherence is measured via self-report, pharmacy records, and

quantification of antiretroviral drug levels in dried blood spots (DBS). Self-reported adherence is measured as

30-day adherence on a visual analogue scale (VAS) of 0 to 100.(30) Pharmacy records are captured as part of 223 routine care in the electronic medical record. Drug pick-up adherence based on medication possession ratio 224 (MPR) will be calculated from pharmacy records, (28, 29) using drug pick-up records over each 24-week period, 225 as total number of days' supply obtained including the last fill, divided by number of days between first fill and 226 last day of the observation window (40). Five 50µL blood spots are collected on protein saver cards (DBS) for 227 measurement of antiretroviral drug levels. The samples are dried out at room temperature for 24 hours, then 228 sealed tightly with desiccant and a humidity indicator, and stored at -20 degrees Celsius until analysis. Clinic 229 visit and pharmacy records are abstracted from medical records onto case report forms and entered in REDCap. 230 Both VAS and MPR values will be evaluated as dichotomous indicators of  $\geq$  90% adherence (good) or < 90% 231 adherence (poor).(41) 232

233

#### 234 Statistical analysis

Several data quality checks will be conducted prior to analysis, including analysis of descriptive statistics and 235 graphic plots to detect appropriate range of variables and to detect missing data or invalid cases. All data are 236 stored in a password-protected network server with daily back-up. For descriptive statistics, percentages will be 237 presented for dichotomous outcomes (e.g., viral suppression vs. non-suppression) and means will be presented 238 for continuous outcomes (e.g., medication adherence). Similarly, changes between intervention and control 239 periods will be summarized via odds ratios. Generalized estimating equations (GEE) will be used to account for 240 multiple observations of participants. A binomial distribution and logit link function will be used to evaluate the 241 statistical significance of the intervention effect, while controlling for secular trends in the outcomes over time 242 and clustering within clusters. This analysis will follow the principles of intention-to-treat analysis and will be 243 evaluated by examining the statistical significance of the regression coefficient for the intervention on the 244 primary outcome. For differences in viral load suppression, we will compare intervention and control periods at 245

- the end of the intervention period, i.e., 48 weeks. Data collected during the follow-up period will be analyzed to
- explore the durability or "post-dose effect" of the intervention.
- 248

#### 249 Sample size calculation

- 250 With a small to moderate within cluster correlation and moderate individual autocorrelation (0.50), this analysis
- will have adequate power (power = 0.945) to detect an OR of 1.5 in the proportion of participants achieving viral
- suppression with at least 90 participants per site.
- 253 Primary study data will be analyzed as soon as possible after the end of data collection, with study findings
- disseminated in peer-review public health journals.

255

# 256 Discussion

We describe herein the design of a stepped wedge trial of the iCARE-Treatment intervention, a combination of 257 peer navigation and text message reminders to promote viral suppression among youth living with HIV in 258 Nigeria, aged 15-24 years. The intervention draws on evidence-based intervention approaches that we adapted 259 to the Nigerian context through broad stakeholder input in the formative stage of study design. Following the 260 pre-post pilot trial in the UG3 phase of this study with evidence of initial efficacy and feasibility, we sought to 261 extend the evidence from the UG3 to a much larger sample in the UH3 study described herein. The design of 262 this UH3 study has several additional strengths, including inclusion of youth living with HIV in multiple states 263 and regions of Nigeria, using a practical stepped wedge design that ensures every cluster receives the 264 intervention, and incorporating a combination of evidence-based intervention approaches. 265

266

iCARE-Treatment is among the first interventions to be tested in a rigorous trial of sufficient size to detect
 effects on ART outcomes in youth. Effective interventions are needed urgently, particularly in a country like

Nigeria that has met none of the key metrics recommended by Joint United Nations Programme on HIV/AIDS 269 (UNAIDS) for measuring progress in reducing the public health threat of HIV.(11, 42) Illustratively, AIDS-270 related deaths from 2010 to 2020 fell by only 28% compared to the target of 75% decline.(11) Since youth are 271 known to fare worse than older persons on the cascade of HIV care, (43, 44) interventions like iCARE-272 Treatment are needed to improve viral suppression in youth; sustained viral suppression is the gateway to lower 273 morbidity and mortality and elimination of viral transmission.(45-47) In designing this UH3 trial, our team is 274 mindful of the need to understand potential barriers to broad adoption and scale-up of the iCARE-Treatment 275 intervention should the results from the UG3 pilot be replicated in the UH3 study. As such, we intend to collect 276 data on potential implementation barriers and facilitators, including cost implications, during the UH3 study and 277 provide public health collaborators and policy makers with a comprehensive summary of evidence at the end of 278 the study. 279

280

281

282

# 283 Acknowledgements

We would like to thank members of the iCARE team at all study sites for their contribution to the study 284 protocol and procedures. This publication was supported by funding from the Eunice Kennedy Shriver National 285 Institute of Child Health & Human Development of the National Institutes of Health under Award Number 286 UH3HD096920. The content is solely the responsibility of the authors and does not necessarily represent the 287 official views of the National Institutes of Health. Research reported in this publication was also supported by 288 the Fogarty International Center of the National Institutes of Health under Award Number D43TW009608, and 289 by the National Institutes of Health's National Center for Advancing Translational Sciences, Grant Number 290 UL1TR001422. The funding source has no role in the original design of this study, analysis and interpretation 291 of data, or decision to submit results. 292

#### 293 Ethics approval

This protocol has been approved by the Institutional Review Boards of Northwestern University 294 (STU00214317-CR0001), Ann & Robert H. Lurie Children's Hospital of Chicago, College of Medicine, 295 University of Ibadan/University College Hospital; Lagos State University Teaching Hospital, Lagos University 296 Teaching Hospital, Nigerian Institute of Medical Research; Jos University Teaching Hospital and Olabisi 297 Onabanjo University Teaching Hospital respectively, with a waiver of parental permission for participation of 298 minors (aged 16-17). Current protocol version: March 11, 2022. Any modifications to the protocol are 299 submitted to and approved by the IRBs of Record prior to implementation. Spontaneously reported adverse 300 events and unintended effects of the trial are tracked by the study Principal Investigators and reported to the 301 IRBs of Record. Study participants complete a written informed assent or consent process prior to participation 302 in research activities. This study is monitored by a Data Safety and Monitoring Board (DSMB), the composition 303 of which may be obtained from the study Principal Investigator at the lead institution. The trial will be 304

	medRxiv preprint doi: https://doi.org/10.1101/2022.08.22.22279094; this version posted August 23, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.
305	suspended or stopped if recommended by the DSMB and the study investigators, in consultation with the study
306	sponsor, determine that, in their clinical opinion, there are risks to participants for continuation.
307	
308	
309	Availability of data
310	Trial data will be archived and publicly available at the National Institute of Child Health and Human
311	Development Data and Specimen Hub.
312	
313	Authors' contributions
314	BT, RG and LK contributed to the design of all aspects of the study. All authors contributed to the study design
315	and selection of measures. PJ designed the proposed data analysis. BT, RB and LK drafted the manuscript. The
316	manuscript has been read and approved by all authors.
317	
318	
319	
320	
321	
322	

#### 323 **References**

324 325 326 327 328	<ol> <li>Federal Ministry of Health of Nigeria. National guidelines for HIV prevention, treatment and care, 2016. 2016.</li> <li>Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. The New England journal of medicine. 2011;365(6):493-505.</li> <li>Insight Start Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. The New England journal of medicine. 2015;373(9):795-</li> </ol>
329	807.
330	4. Temprano Anrs Study Group, Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, et al. A Trial of Early
331	Antiretrovirals and Isoniazid Preventive Therapy in Africa. The New England journal of medicine. 2015;373(9):808-22.
332	5. Auld AF, Agolory SG, Shiraishi RW, Wabwire-Mangen F, Kwesigabo G, Mulenga M, et al. Antiretroviral
333	therapy enrollment characteristics and outcomes among HIV-infected adolescents and young adults compared with older
334	adultsseven African countries, 2004-2013. MMWR Morb Mortal Wkly Rep. 2014;63(47):1097-103.
335	6. DeSilva MB, Merry SP, Fischer PR, Rohrer JE, Isichei CO, Cha SS. Youth, unemployment, and male gender
336	predict mortality in AIDS patients started on HAART in Nigeria. AIDS Care. 2009;21(1):70-7.
337	7. Mark D, Armstrong A, Andrade C, Penazzato M, Hatane L, Taing L, et al. HIV treatment and care services for
338	adolescents: a situational analysis of 218 facilities in 23 sub-Saharan African countries. J Int AIDS Soc. 2017;20(Suppl
339	3):21591.
340	8. UNAIDS. Fast Track-Ending the AIDS Epidemic by 2030. Geneva, Switzerland: Joint United Nations
341	Programme on HIV/AIDS; 2014.
342	9. United Nations General Assembly. Convention on the rights of the child. New York, NY: United Nations; 1989.
343	10. UNAIDS. Young people and HIV. unaids.org: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2021
344	11. AIDSinfo [Internet]. UNAIDS. 2020 [cited December 6, 2021].
345	12. NAIIS Consortium. Nigeria HIV/AIDS Indicator and Impact Survey: National Summary Sheet. 2019.
346	13. Simoni JM, Nelson KM, Franks JC, Yard SS, Lehavot K. Are peer interventions for HIV efficacious? A
347	<ul> <li>systematic review. AIDS Behav. 2011;15(8):1589-95.</li> <li>14. Genberg BL, Shangani S, Sabatino K, Rachlis B, Wachira J, Braitstein P, et al. Improving Engagement in the HIT</li> </ul>
348 349	Care Cascade: A Systematic Review of Interventions Involving People Living with HIV/AIDS as Peers. AIDS Behav.
350	2016;20(10):2452-63.
351	15. World Health Organization. HIV and adolescents: Guidance for HIV testing and counselling and care for
352	adolescents living with HIV. Geneva, Switzerland: World Health Organization; 2013.
353	16. Mulawa MI, LeGrand S, Hightow-Weidman LB. eHealth to Enhance Treatment Adherence Among Youth Living
354	with HIV. Curr HIV/AIDS Rep. 2018;15(4):336-49.
355	17. Cao B, Gupta S, Wang J, Hightow-Weidman LB, Muessig KE, Tang W, et al. Social Media Interventions to
356	Promote HIV Testing, Linkage, Adherence, and Retention: Systematic Review and Meta-Analysis. J Med Internet Res.
357	2017;19(11):e394.
358	18. Schnall R, Travers J, Rojas M, Carballo-Dieguez A. eHealth interventions for HIV prevention in high-risk men
359	who have sex with men: a systematic review. J Med Internet Res. 2014;16(5):e134.
360	19. Catalani C, Philbrick W, Fraser H, Mechael P, Israelski DM. mHealth for HIV Treatment & Prevention: A
361	Systematic Review of the Literature. Open AIDS J. 2013;7:17-41.
362	20. Devi BR, Syed-Abdul S, Kumar A, Iqbal U, Nguyen PA, Li YC, et al. mHealth: An updated systematic review
363	with a focus on HIV/AIDS and tuberculosis long term management using mobile phones. Comput Methods Programs
364	Biomed. 2015;122(2):257-65.
365	21. Garofalo R, Kuhns LM, Hotton A, Johnson A, Muldoon A, Rice D. A Randomized Controlled Trial of
366	Personalized Text Message Reminders to Promote Medication Adherence Among HIV-Positive Adolescents and Young
367	<ul> <li>Adults. AIDS Behav. 2016;20(5):1049-59.</li> <li>Bandura A. The anatomy of stages of change. Am J Health Promot. 1997;12(1):8-10.</li> </ul>
368 369	<ol> <li>Bandura A. The anatomy of stages of change. And Freath Fromot. 1997,12(1):8-10.</li> <li>Bandura A. Health promotion by social cognitive means. Health Educ Behav. 2004;31(2):143-64.</li> </ol>
370	<ul> <li>23. Bandura A. Health promotion by social cognitive means. Health Educ Benav. 2004, 51(2):145-04.</li> <li>24. Taiwo BO, Kuti KM, Kuhns LM, Omigbodun O, Awolude O, Adetunji A, et al. Effect of Text Messaging Plus</li> </ul>
371	Peer Navigation on Viral Suppression Among Youth With HIV in the iCARE Nigeria Pilot Study. J Acquir Immune Defi
372	Syndr. 2021;87(4):1086-92.
373	25. Kuhns LM, Johnson AK, Adetunji A, Kuti KM, Garofalo R, Omigbodun O, et al. Adaptation of evidence-based
374	approaches to promote HIV testing and treatment engagement among high-risk Nigerian youth. PLoS One.
375	2021;16(10):e0258190.

- Dowshen N, Kuhns LM, Gray C, Lee S, Garofalo R. Feasibility of interactive text message response (ITR) as a 376 26. novel, real-time measure of adherence to antiretroviral therapy for HIV+ youth. AIDS Behav. 2013;17(6):2237-43. 377 Federal Ministry of Health Nigeria. National guidelines for HIV prevention, treatment and care. National AIDS 27. 378 and STIs Control Programme, ; 2020. 379 Grossberg R, Zhang Y, Gross R. A time-to-prescription-refill measure of antiretroviral adherence predicted 380 28. changes in viral load in HIV. J Clin Epidemiol. 2004:57(10):1107-10. 381 McMahon JH, Jordan MR, Kelley K, Bertagnolio S, Hong SY, Wanke CA, et al. Pharmacy adherence measures 382 29. to assess adherence to antiretroviral therapy: review of the literature and implications for treatment monitoring. Clin Infect 383 Dis. 2011;52(4):493-506. 384 Finitsis DJ, Pellowski JA, Huedo-Medina TB, Fox MC, Kalichman SC, Visual analogue scale (VAS) 385 30. measurement of antiretroviral adherence in people living with HIV (PLWH): a meta-analysis. J Behav Med. 386 2016;39(6):1043-55. 387 Balfour L, Kowal J, Tasca GA, Cooper CL, Angel JB, Macpherson PA, et al. Development and psychometric 388 31. validation of the HIV Treatment Knowledge Scale. AIDS Care. 2007;19(9):1141-8. 389 Erlen JA, Cha ES, Kim KH, Caruthers D, Sereika SM. The HIV Medication Taking Self-efficacy Scale: 32. 390 psychometric evaluation. J Adv Nurs. 2010;66(11):2560-72. 391 Wright K, Naar-King S, Lam P, Templin T, Frey M. Stigma scale revised: reliability and validity of a brief 33. 392 measure of stigma for HIV+ youth. J Adolesc Health. 2007;40(1):96-8. 393 34. Richardson LP, McCauley E, Grossman DC, McCarty CA, Richards J, Russo JE, et al. Evaluation of the Patient 394 Health Questionnaire-9 Item for detecting major depression among adolescents. Pediatrics. 2010;126(6):1117-23. 395 396 35. Humeniuk R. Validation of the alcohol, smoking and substance involvement screening test (ASSIST) and pilot brief intervention: A technical report of phase II findings of the WHO ASSIST project. Geneva, Switzerland: World 397 Health Organization; 2006. 398 Attkisson CC GT. Client satisfaction questionnaire-8 and service satisfaction scale-30. In: Maruish ME e, editor. 36. 399 The Use of Psychological Testing for Treatment Planning and Outcome Assessment. Hillsdale, NJ: Lawrence Erlbaum 400 Associates, Inc; 1994. p. 402-20. 401 Proctor E, Silmere H, Raghavan R, Hovmand P, Aarons G, Bunger A, et al. Outcomes for implementation 37. 402 research: conceptual distinctions, measurement challenges, and research agenda. Adm Policy Ment Health. 403 2011;38(2):65-76. 404 Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowerv JC, Fostering implementation of health 405 38 services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 406 2009;4:50. 407 Tanner MR, Bush T, Nesheim SR, Weidle PJ, Byrd KK. Retention in Medical Care Among Insured Children with 39. 408 Diagnosed HIV Infection - United States, 2010-2014. MMWR Morb Mortal Wkly Rep. 2017;66(39):1033-8. 409 40. Vollmer WM, Xu M, Feldstein A, Smith D, Waterbury A, Rand C. Comparison of pharmacy-based measures of 410 medication adherence. BMC Health Serv Res. 2012:12:155. 411 Kahana SY, Rohan J, Allison S, Frazier TW, Drotar D. A meta-analysis of adherence to antiretroviral therapy and 41. 412 virologic responses in HIV-infected children, adolescents, and young adults. AIDS Behav. 2013;17(1):41-60. 413 42. Ghys PD, Williams BG, Over M, Hallett TB, Godfrey-Faussett P. Epidemiological metrics and benchmarks for a 414 transition in the HIV epidemic. PLoS Med. 2018;15(10):e1002678. 415 Zanoni BC, Mayer KH. The adolescent and young adult HIV cascade of care in the United States; exaggerated 416 43. health disparities. AIDS Patient Care STDS. 2014;28(3):128-35. 417 44. Zanoni BC, Archary M, Buchan S, Katz IT, Haberer JE. Systematic review and meta-analysis of the adolescent 418 HIV continuum of care in South Africa: the Cresting Wave. BMJ Glob Health. 2016;1(3):e000004. 419 Antiretroviral therapy cohort collaboration. Survival of HIV-positive patients starting antiretroviral therapy 420 45. between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017;4(8):e349-e56. 421 Bavinton BR, Pinto AN, Phanuphak N, Grinsztejn B, Prestage GP, Zablotska-Manos IB, et al. Viral suppression 46. 422 423 and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. Lancet HIV. 2018;5(8):e438-e47. 424 Katz IT, Maughan-Brown B, Improved life expectancy of people living with HIV: who is left behind? Lancet 47 425 HIV. 2017;4(8):e324-e6. 426
- 427



# SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	ltem No	Description	Addressed on page number
Administrative info	rmatior	1	
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	P.1, top of page
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	P.3, bottom of page
	2b	All items from the World Health Organization Trial Registration Data Set	See ClinicalTrials.gov
Protocol version	3	Date and version identifier	P.14, first paragraph
Funding	4	Sources and types of financial, material, and other support	P.14, last paragraph
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	P.1, P.16, top of page
	5b	Name and contact information for the trial sponsor	P.14, first paragraph
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	P.14, first paragraph
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	N/A

Introduction

Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	PP.4-5, "Introduction"
	6b	Explanation for choice of comparators	P.5, first paragraph
Objectives	7	Specific objectives or hypotheses	P.5, "Study Objectives"
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	PP.6-7, "Design"
Methods: Participa	nts, inte	erventions, and outcomes	
Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	P.6, first paragraph
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	P.6, last paragraph
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	P.7, last paragraph to P.9 first paragraph
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	N/A
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	P.7, last paragraph to P.9 first paragraph
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	P.9, first paragraph
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	P.9, last paragraph to P.10

Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	_Figure 1, Table 1_
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	P.11, second paragraph
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	P.6, last paragraph_
Methods: Assignme	ent of i	nterventions (for controlled trials)	
Allocation:			
Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	P.7, first paragraph_
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	P.7, first paragraph_
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	P.7, first paragraph_
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	P.7, first paragraph_
	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	N/A
Methods: Data colle	ection,	management, and analysis	
Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	P.9, last paragraph to P.10

	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	P.9, last paragraph to P.10
Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	P.10, last paragraph, P.11, first paragraph
Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	P.10, last paragraph, P.11, first paragraph
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	P.10, last paragraph, P.11, first paragraph
	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	P.11, first paragraph
Methods: Monitoring	g		
Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	P.14, last paragraph
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	_P.15, top of page
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	P.14, last paragraph
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	_P.10, top of the page

Ethics and dissemination

Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	P.14, last paragraph
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	P.14, last paragraph
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	P.9, last paragraph_
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	P.9, last paragraph_
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	P.9, last paragraph_
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	Included in submission system
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	P.15, "availability of data" _
Ancillary and post- trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	N/A
Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	P.11, 2 <sup>nd</sup> section_
	31b	Authorship eligibility guidelines and any intended use of professional writers	N/A
	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	P.15, "availability of data"

Appendices			
Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	To be submitted if requested by the journal
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	N/A

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "Attribution-NonCommercial-NoDerivs 3.0 Unported" license.

	STUDY WEEKS		0-24W	25-48W	49-72W	73-96W
	TIME PERIOD		TIME 1	TIME 2	TIME 3	TIME 4
	Cluster 1: IDI/CoMUI (not randomized)					
	Cluster 2: RANDOMIZED (LASUTH, LUTH, NIMR)					
R (>	Cluster 3: RANDOMIZED (JUT xiv preprint doi: https://doi.org/10.1101/2022.00 vhch washior certified by peer review) is the au This article is a US Government work.	3.22.222 uthor/fun It is not for u	79094; this versio der, who has gra subject to copyri ise under a CC0 i	on posted August nted medRxiv a li ght under 17 USC license.	23, 2022. The co cense to display f 105 and is also	pyright holder for he preprint in per made available
	Control (Pre-Intervention) Phase					
	Intervention Phase					
	Follow-up (Post- Intervention) Phase					

# Figure 2